Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG (MOLN) is a clinical-stage biotech company whose news flow is closely tied to the progress of its DARPin-based oncology pipeline. The company regularly issues updates on its clinical trials, preclinical data presentations and strategic collaborations, giving investors and observers insight into how its programs are advancing through development.
News about Molecular Partners often highlights milestones for its Radio-DARPin platform, including MP0712, a 212Pb-based candidate targeting DLL3 in small cell lung cancer and other neuroendocrine cancers, and MP0726, which targets mesothelin in cancers with high unmet need. Press releases describe regulatory steps such as Investigational New Drug applications, initiation of Phase 1/2a studies, and early human imaging data from compassionate care programs, as well as the role of its collaboration with Orano Med in radiotherapeutics.
Another major source of updates is the companys multispecific T cell engager MP0533, in Phase 1/2a for relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome/AML. Molecular Partners reports interim clinical data, dosing refinements and response patterns, particularly in patients with lower disease burden, through conference presentations and ad hoc announcements. News items also cover MP0317, a tumor-localized CD40 agonist in an investigator-initiated Phase 2 trial in cholangiocarcinoma, and preclinical Switch-DARPin programs that use logic-gated immune activation.
Corporate communications further include quarterly and half-year financial results, cash runway commentary, and management changes such as the appointment of a Chief Scientific Officer. For readers following MOLN stock, this news page provides a centralized view of regulatory disclosures, scientific conference presentations and pipeline progress updates related to Molecular Partners DARPin therapeutics.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced participation by CEO Patrick Amstutz, Ph.D., in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 8:00 AM EST. The presentation will be webcasted and available on the company’s website. Molecular Partners focuses on developing DARPin therapeutics for various diseases, including oncology and infectious diseases, partnering with leading pharmaceutical companies to enhance clinical and preclinical development.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced that the Data and Safety Monitoring Board (DSMB) has recommended halting the recruitment of patients for the ensovibep arm in the ACTIV-3 COVID-19 clinical study for hospitalized patients, as it did not meet required futility thresholds. While ensovibep remains well-tolerated, the study highlights challenges in demonstrating efficacy in late-stage COVID-19. Meanwhile, the ongoing EMPATHY study is assessing ensovibep's efficacy in non-hospitalized patients, with topline data anticipated in early 2022.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has initiated a Phase 1 clinical trial for MP0317, its second immuno-oncology DARPin candidate. This therapy aims to deliver tumor-localized immune activation while minimizing systemic toxicity, a common issue with existing CD40-targeting agents. Preclinical results indicate MP0317 can activate immune cells effectively within tumors. The open-label study will enroll up to 30 patients across six cohorts in Europe, assessing safety, tolerability, and pharmacodynamics. The innovative DARPin technology may enhance the efficacy of cancer immunotherapies while protecting healthy tissue.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced its interim management statement for Q3 2021, highlighting advancements in its COVID-19 program. The company has enrolled over 700 patients in two global studies and is preparing for significant data assessments. Financially, as of September 30, 2021, it reported CHF 154.3 million in cash, with an operating loss of CHF 47.6 million. The company expects total expenses for 2021 to be between CHF 70-75 million. Topline data from ongoing trials are expected in early 2022, marking critical milestones for the company's therapeutic candidates.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the presentation of in vitro data for their COVID-19 therapeutic, ensovibep, at the ISIRV and WHO conference. The data confirms ensovibep's ability to inhibit all known SARS-CoV-2 variants of concern, including the Delta variant. The company will also present a Trial in Progress poster on the EMPATHY clinical trial, which evaluates ensovibep's efficacy in COVID-19 patients. Ensovibep is currently in late-stage trials, highlighting its potential in addressing unmet treatment needs amidst evolving variants.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a biotech firm specializing in DARPin® therapeutics, announced that CEO Patrick Amstutz will present at two virtual healthcare investor events in September 2021. The first event is the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, happening from September 13-15, with presentations available on demand from September 13 at 7:00 AM ET. Webcasted presentations will be accessible on the company's website.
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) announced significant advancements in its COVID-19 therapeutic trials, particularly its lead candidate ensovibep. Two late-stage trials, EMPATHY and ACTIV-3, have been initiated with positive interim data expected in the second half of 2021. The FDA awarded Fast Track designation for ensovibep, which maintains efficacy against SARS-CoV-2 variants. Financial results for H1 2021 showed revenues of CHF 4.4 million, but the firm reported an operating loss of CHF 34.8 million, reflecting rising expenses and ongoing cash utilization. Cash reserves stand at CHF 174.3 million, supporting operations until H2 2023.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) announced the return of global rights to its investigational drug abicipar pegol from AbbVie due to the termination of their collaboration agreement. This drug targets neovascular age-related macular degeneration (nAMD) and Diabetic Macular Edema (DME). Molecular Partners has made improvements in the drug's manufacturing and formulation to potentially reduce inflammatory side effects. The company plans to evaluate next steps for abicipar while continuing its discovery alliance with AbbVie for other ophthalmic therapies.
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) reports progress on its antiviral candidate, ensovibep, designed to combat SARS-CoV-2. It retains full potency against all known variants, including Delta. The EMPATHY Phase 2/3 trial is enrolling patients across 5 countries, with expansion planned. The ACTIV-3 trial for hospitalized patients is actively recruiting. A subcutaneous formulation is set for clinical trials in H2 2021. Ensovibep shows potential for differentiated treatment amid mixed vaccination rates globally.